Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 28, 2026, 5:56 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 841–864 of 3,499 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Protein Control Clear all
Terminated Phase 2Phase 3 Interventional

Effect of Pulsatile IV Insulin on Circulating Risk Markers of Vascular and Metabolic Complications in Pts With Diabetes

NCT00361907
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
Effect of Pulsatile IV insulin on diabetic pt blood markers, Effect of Pulsatile IV Insulin on blood markers
Procedure
Lead sponsor
Florida Atlantic University
Other
Eligibility
21 Years to 85 Years
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
Boca Raton, Florida
Source: ClinicalTrials.gov public record
Updated Aug 9, 2016 · Synced Oct 28, 2026, 5:56 AM EDT
Recruiting Phase 3 Interventional

A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer

NCT06532006
View directory record Official record
Conditions
Gastroesophageal-junction Cancer, Monoclonal Antibody, Gastric Cancer, HER2-positive Gastric Cancer
Interventions
HLX22, Pembrolizumab, Trastuzumab, Oxaliplatin, Capecitabine
Drug
Lead sponsor
Shanghai Henlius Biotech
Industry
Eligibility
18 Years and older
Enrollment
550 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
29
States / cities
Anaheim, California • Los Alamitos, California • Greeley, Colorado + 24 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2026 · Synced Oct 28, 2026, 5:56 AM EDT
Completed Phase 3 Interventional Results available

A Trial to Compare the Efficacy and Safety of Once-weekly Lonapegsomatropin With Placebo and a Daily Somatropin Product in Adults With Growth Hormone Deficiency

NCT04615273
View directory record Official record
Conditions
Growth Hormone Deficiency, Endocrine System Diseases, Hormone Deficiency
Interventions
Lonapegsomatropin, Placebo, Somatropin
Drug · Other
Lead sponsor
Ascendis Pharma Endocrinology Division A/S
Industry
Eligibility
23 Years to 80 Years
Enrollment
264 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
23
States / cities
Birmingham, Alabama • Phoenix, Arizona • Fresno, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Oct 28, 2026, 5:56 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

The Role of Cytokines on Growth Hormone Suppression in Premenopausal Women With Rheumatoid Arthritis and the Effect of Treatment With Etanercept

NCT00034060
View directory record Official record
Conditions
Rheumatoid Arthritis, Healthy
Interventions
Etanercept
Drug
Lead sponsor
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
NIH
Eligibility
Female only
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2005
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 28, 2026, 5:56 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Diet as a Potential Treatment for Autosomal Dominant Polycystic Kidney Disease

NCT02225860
View directory record Official record
Conditions
Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Interventions
Diet and water adjustment
Behavioral
Lead sponsor
Tufts Medical Center
Other
Eligibility
18 Years to 60 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 30, 2017 · Synced Oct 28, 2026, 5:56 AM EDT
Active, not recruiting Phase 2 Interventional

Phase 2 Study Evaluating Rapcabtagene Autoleucel in Participants With Diffuse Cutaneous Systemic Sclerosis

NCT06655896
View directory record Official record
Conditions
Scleroderma, Diffuse
Interventions
rapcabtagene autoleucel, rituximab
Biological
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 70 Years
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2032
U.S. locations
13
States / cities
Los Angeles, California • San Francisco, California • San Pablo, California + 10 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Oct 28, 2026, 5:56 AM EDT
Completed Phase 2 Interventional Results available

LCZ696 Compared to Valsartan in Patients With Chronic Heart Failure and Preserved Left-ventricular Ejection Fraction

NCT00887588
View directory record Official record
Conditions
Chronic Heart Failure
Interventions
LCZ696, Valsartan, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
40 Years and older
Enrollment
307 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
11
States / cities
Little Rock, Arkansas • Chicago, Illinois • Detroit, Michigan + 8 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2015 · Synced Oct 28, 2026, 5:56 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Effect of a Fermented Dairy Protein With Prebiotic Fiber on GI Complaints

NCT06946017
View directory record Official record
Conditions
Digestive Health, Quality of Life
Interventions
Fermented dairy protein with prebiotic fiber supplement, Control placebo
Dietary Supplement
Lead sponsor
Arizona State University
Other
Eligibility
18 Years to 50 Years
Enrollment
114 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated May 8, 2026 · Synced Oct 28, 2026, 5:56 AM EDT
Completed Not applicable Interventional Results available

Goal-Directed Intraoperative Fluid Management Using FloTrac© Monitoring in High-Risk Neurosurgical Patients

NCT02701582
View directory record Official record
Conditions
Intracranial Aneurysm, Brain Edema, Scoliosis, Surgery
Interventions
Phenylephrine, Epinephrine, Albumin, Voluven, Normal Saline, Packed Red Blood Cells, FloTrac Monitor
Drug · Other · Device
Lead sponsor
NYU Langone Health
Other
Eligibility
15 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 28, 2019 · Synced Oct 28, 2026, 5:56 AM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Safety, Tolerability, and Weight Loss Efficacy of K-757 Alone and in Combination With K-833

NCT06019559
View directory record Official record
Conditions
Obesity
Interventions
K-757 120 mg BID and K-833 100 mg BID, K-757 120 mg BID and matching placebo to K-833, Matching placebo to K-757 and matching placebo to K-833
Drug
Lead sponsor
Kallyope Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
155 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
22
States / cities
San Diego, California • Stockbridge, Georgia • Topeka, Kansas + 19 more
Source: ClinicalTrials.gov public record
Updated Feb 26, 2025 · Synced Oct 28, 2026, 5:56 AM EDT
Withdrawn Phase 4 Interventional

Does Pregabalin Improve Symptoms of Anxiety in Patients With Epilepsy? A Comparison With Sertraline

NCT01309074
View directory record Official record
Conditions
Epilepsy, Anxiety
Interventions
Pregabalin-Lyrica, Sertraline
Drug
Lead sponsor
Rush University Medical Center
Other
Eligibility
18 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 2, 2023 · Synced Oct 28, 2026, 5:56 AM EDT
Completed Phase 3 Interventional Results available

A Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drugs (DMARD)-naïve Adults With Early Active Rheumatoid Arthritis

NCT01521923
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Certolizumab Pegol + Methotrexate (MTX), Placebo + Methotrexate (MTX)
Biological
Lead sponsor
UCB Pharma
Industry
Eligibility
18 Years and older
Enrollment
359 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
70
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 63 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Oct 28, 2026, 5:56 AM EDT
Terminated Phase 2 Interventional Results available

Metyrosine (Demser®) for the Treatment of Psychotic Disorders in Patients With Velocardiofacial Syndrome

NCT01127503
View directory record Official record
Conditions
Velo-cardio-facial Syndrome, Psychosis
Interventions
Metyrosine, Placebo
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
16 Years to 65 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Syracuse, New York
Source: ClinicalTrials.gov public record
Updated Nov 22, 2019 · Synced Oct 28, 2026, 5:56 AM EDT
Completed Phase 2 Interventional

A Study to Evaluate ASP8232 in Reducing Central Retinal Thickness in Subjects With Diabetic Macular Edema (DME)

NCT02302079
View directory record Official record
Conditions
Diabetes Mellitus, Diabetic Macular Edema
Interventions
ASP8232, ranibizumab, Placebo, Sham intravitreal (IVT) injection
Drug · Other
Lead sponsor
Astellas Pharma Europe B.V.
Industry
Eligibility
18 Years to 85 Years
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
21
States / cities
Phoenix, Arizona • Tucson, Arizona • Arcadia, California + 18 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2024 · Synced Oct 28, 2026, 5:56 AM EDT
Completed Phase 3 Interventional Results available

Remission in Subjects With Crohn's Disease, 1 Year Phase

NCT00055497
View directory record Official record
Conditions
Crohn's Disease
Interventions
Double-blind (DB) adalimumab placebo, DB adalimumab 40 mg eow, DB adalimumab 40 mg ew, OL adalimumab 40 mg
Biological
Lead sponsor
Abbott
Industry
Eligibility
18 Years to 75 Years
Enrollment
276 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2008
U.S. locations
43
States / cities
Berkeley, California • Long Beach, California • San Diego, California + 36 more
Source: ClinicalTrials.gov public record
Updated Apr 11, 2011 · Synced Oct 28, 2026, 5:56 AM EDT
Completed Phase 1 Interventional

Phase I Oncovir Poly IC:LC and NY-ESO-1/gp100

NCT01008527
View directory record Official record
Conditions
Melanoma
Interventions
CP 870,893, Peptides, Oncovir poly IC:LC
Drug · Biological
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Sep 24, 2015 · Synced Oct 28, 2026, 5:56 AM EDT
Completed Phase 2 Interventional

Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Malignant Mesothelioma

NCT00027703
View directory record Official record
Conditions
Advanced Malignant Mesothelioma, Epithelial Mesothelioma, Localized Malignant Mesothelioma, Recurrent Malignant Mesothelioma, Sarcomatous Mesothelioma
Interventions
gemcitabine hydrochloride, cisplatin, bevacizumab, placebo, laboratory biomarker analysis
Drug · Biological · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 11, 2014 · Synced Oct 28, 2026, 5:56 AM EDT
Completed Not applicable Interventional

The Effects of Perioperative Nutritional Optimization on Blood Markers

NCT04464161
View directory record Official record
Conditions
Intervertebral Disc Disorders With Radiculopathy, Lumbar Region
Interventions
Ensure
Dietary Supplement
Lead sponsor
NYU Langone Health
Other
Eligibility
55 Years to 100 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 22, 2022 · Synced Oct 28, 2026, 5:56 AM EDT
Completed Phase 2 Interventional

Early Protein Supplementation of Human Milk in Extremely Low Birth Weight Infants

NCT01991613
View directory record Official record
Conditions
Growth in Premature Infants
Interventions
liquid protein supplement
Dietary Supplement
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
26 Weeks to 33 Weeks
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 23, 2015 · Synced Oct 28, 2026, 5:56 AM EDT
Completed Phase 2 Interventional

Vitamin D3 Supplementation for Heart Failure Patients

NCT01636570
View directory record Official record
Conditions
Heart Failure, Vitamin D Deficiency, Cardiomyopathy, Congestive Heart Failure
Interventions
Placebo Comparator: Sugar Pill, Vitamin D3 (cholecalciferol)
Drug
Lead sponsor
Heidi Moretti, MS, RD
Other
Eligibility
Not listed
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
2
States / cities
Missoula, Montana
Source: ClinicalTrials.gov public record
Updated Apr 26, 2017 · Synced Oct 28, 2026, 5:56 AM EDT
Completed Phase 3 Interventional Results available

A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Who Have Obesity or Are Overweight

NCT04657003
View directory record Official record
Conditions
Type 2 Diabetes, Overweight, Obesity
Interventions
Tirzepatide, Placebo
Drug · Other
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
938 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
43
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Huntington Park, California + 39 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2024 · Synced Oct 28, 2026, 5:56 AM EDT
Completed Not applicable Interventional

Impact of a LCD on Metabolic Inflexibility and Cardiovascular Risk in Liver Transplant Patients

NCT04145427
View directory record Official record
Conditions
Weight Gain
Interventions
Control, LCD
Behavioral
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 20, 2024 · Synced Oct 28, 2026, 5:56 AM EDT
Not listed Not applicable Interventional

Growth and Nutritional Status of Very Low Birth Weight Infants Fed a High Protein Exclusive Human Milk Diet

NCT03839173
View directory record Official record
Conditions
Premature Infant, Breast Milk Expression
Interventions
Human milk based human milk fortifier
Other
Lead sponsor
Augusta University
Other
Eligibility
23 Weeks to 33 Weeks
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Augusta, Georgia
Source: ClinicalTrials.gov public record
Updated Jul 29, 2019 · Synced Oct 28, 2026, 5:56 AM EDT
Terminated Early Phase 1 Interventional

PCSK9 Inhibition in Patients With Symptomatic Intracranial Atherosclerosis

NCT03507374
View directory record Official record
Conditions
Stroke, Intracranial Atherosclerosis, Intraplaque Hemorrhage
Interventions
Alirocumab, Placebo
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Apr 21, 2020 · Synced Oct 28, 2026, 5:56 AM EDT